Medtronic PLC $MDT Shares Bought by Creative Financial Designs Inc. ADV

Creative Financial Designs Inc. ADV grew its stake in shares of Medtronic PLC (NYSE:MDT) by 3.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,903 shares of the medical technology company’s stock after acquiring an additional 997 shares during the period. Creative Financial Designs Inc. ADV’s holdings in Medtronic were worth $2,345,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. 1248 Management LLC acquired a new stake in shares of Medtronic during the 1st quarter valued at approximately $26,000. Columbia River Financial Group LLC purchased a new position in shares of Medtronic during the 1st quarter worth approximately $28,000. Twin Tree Management LP purchased a new position in shares of Medtronic during the 1st quarter worth approximately $29,000. Activest Wealth Management increased its stake in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares in the last quarter. Finally, Hughes Financial Services LLC purchased a new position in shares of Medtronic during the 1st quarter worth approximately $32,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William R. Jellison bought 2,500 shares of Medtronic stock in a transaction that occurred on Monday, August 25th. The shares were acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.26% of the company’s stock.

Medtronic Stock Down 0.2%

Shares of NYSE MDT opened at $90.82 on Friday. Medtronic PLC has a 52-week low of $79.29 and a 52-week high of $99.37. The firm has a fifty day moving average of $94.35 and a 200-day moving average of $89.67. The stock has a market capitalization of $116.49 billion, a PE ratio of 25.02, a P/E/G ratio of 2.42 and a beta of 0.78. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. The company had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were issued a dividend of $0.71 per share. The ex-dividend date was Friday, September 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. Medtronic’s payout ratio is presently 78.24%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Stifel Nicolaus raised their price objective on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. UBS Group raised their price objective on shares of Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 20th. Daiwa Capital Markets raised their price objective on shares of Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Robert W. Baird raised their price objective on shares of Medtronic from $94.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 20th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday, July 11th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $102.82.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.